CLI
The CLIO consortium: Optimization of Cerenkov Luminescence Imaging for Image-Guided Cancer Surgery
| Coordinatore | CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT
Organization address
address: BAROSS UTCA 91 95 contact info |
| Nazionalità Coordinatore | Hungary [HU] |
| Totale costo | 1˙722˙280 € |
| EC contributo | 1˙332˙999 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2013 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT
Organization address
address: BAROSS UTCA 91 95 contact info |
HU (BUDAPEST) | coordinator | 631˙901.50 |
| 2 |
LIGHTPOINT MEDICAL LTD
Organization address
address: PARK ROAD CARDINAL POINT contact info |
UK (RICKMANSWORTH HERTFORDSHIRE) | participant | 609˙894.10 |
| 3 |
ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH
Organization address
address: BLASEWITZER STRASSE 78-80 contact info |
DE (DRESDEN) | participant | 91˙204.37 |
| 4 |
ORSZAGOS FREDERIC JOLIOT-CURIE SUGARBIOLOGIAI ES SUGAREGESZSEGUGYI KUTATO INTEZET
Organization address
address: ANNA U 5 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 5 |
SAGENTIA LIMITED
Organization address
address: HARSTON MILL contact info |
UK ("HARSTON, CAMBRIDGE") | participant | 0.00 |
| 6 |
SEMMELWEIS EGYETEM
Organization address
address: Ulloi ut 26 contact info |
HU (BUDAPEST) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cancer is the second largest cause of death and morbidity in Europe, with more than 3 million new cases diagnosed each year. The most effective treatment strategy for most forms of cancer is early detection followed by surgery. However, cancers frequently recur following surgery. For example, nearly 1 in 4 breast cancer patients will see their tumor recur after surgery. The consequences of cancer recurrence include repeat operations, delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic and functional outcomes, emotional distress, and financial cost. The financial costs are staggering. Europe spends €125 billion annually on cancer care, approximately 5% of which is managing post-surgical recurrence.
Tumors recur after surgery primarily due to incomplete excision of the tumor or inadequate clearance of surgical margins. Tumors fail to be completely excised because the surgeon only has the visual appearance of the tumor and palpation to differentiate malignant from benign tissue. Consequently, there is an urgent clinical and market need for improved tools to detect cancerous tissue during surgery.
Real-time imaging during surgery would enable the surgeon to more accurately resect tumors and thereby reduce the likelihood of post-surgical recurrence. Cerenkov luminescence imaging (CLI) is a ground-breaking imaging modality that can provide real-time molecular imaging during surgery
The CLIO consortium will develop a Cerenkov luminescence imaging device for image-guided surgery as well as imaging services for the pharmaceutical and medical device sectors. The imaging services will enable pharmaceutical and medical device clients to improve the efficacy evaluation of pharmaceutical and surgical device products. The consortium contains world-leading expertise in medical device product development, clinical and preclinical imaging, oncologic surgery, and surgical device evaluation.'